A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer
- 1 January 2015
- journal article
- research article
- Published by Elsevier BV in European Urology
- Vol. 67 (1), 100-110
- https://doi.org/10.1016/j.eururo.2014.04.006
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Pazopanib versus Sunitinib in Metastatic Renal-Cell CarcinomaThe New England Journal of Medicine, 2013
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2012
- Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma PatientsClinical Cancer Research, 2012
- Treatment selection in metastatic renal cell carcinoma: expert consensusNature Reviews Clinical Oncology, 2012
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trialThe Lancet Oncology, 2011
- Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trialBritish Journal of Cancer, 2011
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2008
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaThe New England Journal of Medicine, 2007